References

References

[1] VIRJI M A, MERCER D W, HERBERMAN R B.Tumor markers in cancer diagnosis and prognosis[J].A cancer journal for clinicians, 1988, 38:104-126.

[2] KARCZEWSKI K J, SNYDER M P.Integrative omics for health and disease[J].Nature reviews genetics, 2018, 19(5):299-310.

[3] DAGOGO-JACK I, SHAW A.Tumour heterogeneity and resistance to cancer therapies[J].Nature reviews clinical oncology, 2018, 15:81-94.

[4] HRISTOVA V A, CHAN D W.Cancer biomarker discovery and translation: proteomics and beyond[J].Expert review proteomics, 2019, 16(2):93-103.

[5] PHILIP L R, YULIN N H, JASON N M, et al.Multiplexed protein quantitation in saccharomyces cerevisiae using amine-reactive isobaric tagging reagents[J].Molecular &Cellular proteomics, 2004, 3(12):1154-1169.

[6] DAVID J C, YINGWEI H, WILLIAM B, et al.Journal of proteome research, 2018, 17(6) :2205-2215.

[7] RODRIGUEZ H, PENNINGTON S R.Revolutionizing precision oncology through collaborative proteogenomics and data sharing[J].Cell, 2018, 173(3):535-539.

[8] ULLAL A V, PETERSON V, AGASTI S S, et al.Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates[J].Science translational medicine, 2014,6(219):219ra9.

[9] KENNEDY J J, ABBATIELLO S E, KIM K, et al.Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins[J].Nature methods, 2014, 11(2):149-155.

[10] YOU J, KAO A, ROSLYN D, et al.A large-scale and robust dynamic MRM study of colorectal cancer biomarkers[J].Journal of proteomics, 2018, 187:80-92.

[11] SUN S, SHAH P, ESHGHI S T, et al.Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides[J].Nature biotechnol logy, 2016, 34(1):84-88.

[12] DUNN J D, REID G E, BRUENING M L.Techniques for phosphopeptide enrichment prior to analysis by mass spectrometry[J].Mass spectrometry reviews, 2010, 29: 29-54.

[13] ARDITO F, GIULIANI M, PERRONE D, et al.The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (review)[J].International journal of molecular medicine, 2017, 40(2):271-280.

[14] ELEONORA T, FRANCO M.Targeting HER2 in ovarian and uterine cancers: challenges and future directions[J].Gynecologic oncology, 2014, 135(2):364-370.

[15] TOMCZAK K, CZERWIŃSKA P, WIZNEROWICZ M.The cancer genome atlas (TCGA):an immeasurable source of knowledge[J].Contemporary oncology (Pozn), 2015, 19(1A):A68-77.

[16] HEITZER E, IMRAN S H, ROBERTS C S, et al.Current and future perspectives of liquid biopsies in genomics-driven oncology[J].Nature reviews genetics, 2019, 20(2):71-88.

[17] VOGEL C, MARCOTTE E M.Insights into the regulation of protein abundance from proteomic and transcriptomic analyses[J].Nature reviews genetics, 2012, 13:679.

[18] WAGNER P D, SRIVASTAVA S.New paradigms in translational science research in cancer biomarkers[J].American journal of translation research, 2012, 159(4):343-353.

[19] DEVON M C, KRISTOPHER L N, NICHOLAS J S.Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine[J].Human molecular genetics, 2016, 25(R2):R182-R189.

[20] COHEN J D, LI L, WANG Y, et al.Detection and localization of surgically resectable cancers with a multi-analyte blood test[J].Science, 2018, 359(6378):926-930.

[21] MERTINS P, MANI D R, RUGGLES K V, et al.Proteogenomics connects somatic mutations to signalling in breast cancer[J].Nature, 2016, 534(7605):55-62.

[22] ZHANG H, LIU T, ZHANG Z, et al.Integrated proteogenomic characterization of human high-grade serous ovarian cancer[J].Cell, 2016, 166(3):755-765.

[23] EVELYNE A, WILLIAM C C, GEERT B.Translating clinical proteomics: the importance of study design[J].Expert review of proteomics, 2015, 12(3):217-219.

[24] PEPE M S, ETZIONI R, FENG Z, et al.Phases of biomarker development for early detection of cancer[J].Journal of the national cancer institute, 2001, 93(14):1054-1061.

[25] FÜZÉRY A K, JOSHUA J, MARIA M C, et al.Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges[J].Clinical proteomics, 2013, 10(1):13.

[26] LI D, CHAN D W.Proteomic cancer biomarkers from discovery to approval: it’s worth the effort[J].Expert reviews proteomics, 2014, 11(2):135-136.

[27] HEDE KARYN.NCI’s national biospecimen network: too early or too late?[J].Journal of the national cancer institute, 2005, 97(4):247-248.

[28] JOHN E M, HOPPER J L, BECK J C, et al.The breast cancer family registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer[J].Breast cancer research, 2004, 6(4):R375-89.

[29] SOONMYUNG P, STEVEN S, GONG T, et al.A multigene assay to predict recurrence of tamoxifen-treated[J].Node-Negative breast cancer, 2009, 351(27):2817-2826.

[30] CRONIN M, SANGLI C, MEI-LAN L, et al.Analytical validation of the oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer[J].Clinical chemistry, 2007, 53(6):1084-1091.

[31] MAHONEY K M, RENNERT P D, FREEMAN G J.Combination cancer immunotherapy and new immunomodulatory targets[J].Nature reviews drug discovery, 2015, 14(8):561-584.

[32] CAO X.Immunology in China: the past, present and future[J].Nature immunology, 2008,9:339-342.

[33] WU Y, CHEN W, XU Z P, GU W.PD-L1 distribution and perspective for cancer immunotherapyblockade, knockdown, or inhibition[J].Frontiers in immunol, 2019, 10:2022.

[34] RONG H, WEI D, VISWANATHA D S, et al.PD-1 expression in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and large B-cell richter transformation(DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness[J].The American journal of surgical pathology, 2018, 42(7):842-854.

[35] HAN Y, HUANBIN W, CHUSHU L, et al.Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy[J].Frontiers in immunology, 2018, 9:1774.

[36] CHEN D S, MELLMAN I.Oncology meets immunology: the cancer-immunity cycle[J].Immunity, 2013, 39(1):1-10.

[37] TOPALIAN S L, SZNOL M, MCDERMOTT D F, et al.Survival, durable tumor remission,and long-term safety in patients with advanced melanoma receiving nivolumab[J].Journal of clinical oncology, 2014, 32(10):1020-1030.

[38] UKPO O C, THORSTAD W L, LEWIS J S.B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma[J].Head and neck pathology, 2013, 7(2):113-121.

[39] TANG Y, FANG W, ZHANG Y, et al.The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs[J].Oncotarget, 2015, 6(16):14209-14219.

[40] YARCHOAN M, HOPKINS A, JAFFEE E M.Tumor mutational burden and response rate to PD-1 inhibition[J].The New England journal of medicine, 2017, 377(25):2500-2501.

[41] GALUPPINI F, POZZO C A, DECKERT J, et al.Tumor mutation burden: from comprehensive mutational screening to the clinic[J].Cancer cell international, 2019, 19:209.

[42] STEUER C E, RAMALINGAM S S.Tumor mutation burden: leading immunotherapy to the era of precision medicine?[J].Journal of clinical oncology, 2018, 36(7):631-632.

[43] IWAI Y, HAMANISHI J, CHAMOTO K, et al.Cancer immunotherapies targeting the PD-1 signaling pathway[J].Journal of biomedical science, 2017, 24(1):26.

[44] BOUMBER Y.Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer.Journal of thoracic disease, 2018, 10(8): 4689-4693.

[45] LINNEMANN C, VAN BUUREN M, BIES L, et al.High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma[J].Nature medicine, 2015, 21(1):81-85.

[46] STENZINGER A, ALLEN J D, MAAS J, et al.Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions[J].Genes chromosomes cancer, 2019,58(8): 578-588.

[47] CHAN T A, WOLCHOK J D, SNYDER A.Genetic basis for clinical response to CTLA-4 blockade in melanoma[J].The New England journal of medicine, 2015, 373(20):2189-2199.

[48] LESKELA S, ROMERO I, CRISTOBAL E, et al.Mismatch repair deficiency in ovarian carcinoma: frequency, causes, and consequences[J].The American journal of surgical pathology, 2020, 44(5):649-656.

[49] FISHEL R.The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis[J].Cancer research, 2001, 61(20):7369-7374.

[50] LAWRENCE M S, STOJANOV P, POLAK P, et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes[J].Nature, 2013, 499(7457):214-218.

[51] SPIES M, FISHEL R.Mismatch repair during homologous and homeologous recombination[J].Cold spring harbor perspectives in biology, 2015, 7(3): a022657.

[52] BOWEN N, SMITH C E, SRIVATSAN A, et al.Reconstitution of long and short patch mismatch repair reactions using Saccharomyces cerevisiae proteins[C]//Proceedings of the National Academy of Sciences of the United States of America, 2013, 110(46):18472-7.

[53] GOELLNER E M, SMITH C E, CAMPBELL C S, et al.PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair[J].Molecular cell, 2014, 55(2):291-304.(https://www.daowen.com)

[54] HEINEN C D, CYR J L, COOK C, et al.Human MSH2 (hMSH2) protein controls ATP processing by hMSH2-hMSH6[J].The journal of biological chemistry, 2011,286(46):40287-40295.

[55] GUPTA S, GELLERT M, YANG W.Mechanism of mismatch recognition revealed by human MutSβ bound to unpaired DNA loops[J].Nature structural & molecular biology, 2019,19(1):72-78.

[56] PARK J, JEON Y, DAEKIL I, et al.Single-molecule analysis reveals the kinetics and physiological relevance of MutL-ssDNA binding[J].PloS One, 2010, 5(11):e15496.

[57] KADYROV F A, DZANTIEV L, CONSTANTIN N, et al.Endonucleolytic function of MutLα in human mismatch repair[J].Cell, 2006, 126:297-308.

[58] SHIMADA A, KAWASOE Y, HATA Y, et al.MutS stimulates the endonuclease activity of MutL in an ATP-hydrolysis-dependent manner[J].The FEBS journal, 2013, 280(14): 3467-3479.

[59] PLUCIENNIK A, DZANTIEV L, IYER R R, et al.PCNA function in the activation and strand direction of MutLα endonuclease in mismatch repair[C]//Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(37):16066-16071.

[60] MEDINI M G, FEDERICO L, OLIVERA-PIMENTEL M, et al.Ribonucleotides misincorporated into DNA act as strand-discrimination signals in eukaryotic mismatch repair[J].Molecular cell, 2013, 50(3):323-332.

[61] SCOTT A L, JESSICA S W, ANDERS R C, et al.Ribonucleotides are signals for mismatch repair of leading-strand replication errors[J].Molecular cell, 2013, 50(3):437-443.

[62] MARTIN M R, BJÖRN R, RACHEL E R, et al.Enzymatic removal of ribonucleotides from DNA is essential for mammalian genome integrity and development[J].Cell, 2012,149(5):1008-1022.

[63] CHEN B C, LEGANT W R, WANG K, et al.Lattice light-sheet microscopy: imaging molecules to embryos at high spatiotemporal resolution[J].Science, 2014, 346(6208): 1257998.

[64] WON-KI C, JEONG C, KIM D, et al.ATP alters the diffusion mechanics of MutS on mismatched DNA[J].Structure, 2012, 20(7):1264-1274.

[65] WON-KI C, JEONG C, KIM D, et al.MutS switches between two fundamentally distinct clamps during mismatch repair[J].Nature structural & molecular biology, 2011, 18(3):379-385.

[66] FORTIES R A, NORTH J A, JAVAID S, et al.A quantitative model of nucleosome dynamics[J].Nucleic acids research, 2011, 39(19):8306-8313.

[67] GORMAN J, WANG F, REDDING S, et al.Single-molecule imaging reveals target-search mechanisms during DNA mismatch repair[C]//Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(45):E3074-E3083.

[68] FISHEL R, ACHARYA S, BERARDINI M, et al.Signaling mismatch repair: the mechanics of an adenosine-nucleotide molecular switch[J].Cold spring harbor symposia on quantitative biology, 2000, 65:217-224.

[69] SCHMUTTE C, SADOFF M M, SHIM K S, et al.The interaction of DNA mismatch repair proteins with human exonuclease I[J].The journal of biological chemistry.2001,276(35):33011-33018.

[70] HOMBAUER H, CAMPBELL C S, SMITH C E, et al.Visualization of eukaryotic DNA mismatch repair reveals distinct recognition and repair intermediates[J].Cell, 2011,147(5):1040-1053.

[71] CORTES-CIRIANO I, SEJOON L, WOONG-YANG P, et al.A molecular portrait of microsatellite instability across multiple cancers[J].Nature communications, 2017, 8:15180.

[72] YUZA K, NAGAHASHI M, WATANABE S, et al.Hypermutation and microsatellite instability in gastrointestinal cancers[J].Oncotarget, 2017, 8(67):112103-112115.

[73] DUDLEY J C, MING-TSEH L, LE D T, et al.Microsatellite instability as a biomarker for PD-1 blockade[J].Clinical cancer research, 2016, 22(4):813-820.

[74] VANESSA D, MARC B, WIM W, et al.Detection of microsatellite instability in colorectal cancer using an alternative multiplex assay of quasi-monomorphic mononucleotide markers[J].The journal of molecular diagnostics, 2008, 10(2):154-159.

[75] KARIN D B, CYNTHIA L G, RICHARD E T, et al.Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction[J].The journal of molecular diagnostics,2000, 2(1):20-28.

[76] RATTI M, LAMPIS A, HAHNE J C, et al.Microsatellite instability in gastric cancer:molecular bases, clinical perspectives, and new treatment approaches[J].Cellular and molecular life sciences, 2018, 17:5.

[77] RIGAU V, SEBBAGH N, OLSCHWANG S, et al.The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining[J].Archives of pathology & laboratory medicine, 2003, 127(6):694-700.

[78] PEREZ-MUÑOZ M E, ARRIETA M C, RAMER-TAIT A E, et al.A critical assessment of the “sterile womb”and “in utero colonisation” hypotheses: implications for research on the pioneer infant microbiome[J].Microbiome, 2017, 5:48.

[79] MILLS S, STANTON C, LANE J A, et al.Precision nutrition and the microbiome, part I:current state of the science[J].Nutrients, 2019, 11(4):923.

[80] HILL C J, LYNCH D B, MURPHY K, et al.Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort[J].Microbiome, 2017, 5(1):4.

[81] YASMIN F, TUN H M, KONYA T B, et al.Cesarean section, formula feeding, and infant antibiotic exposure: separate and combined impacts on gut microbial changes in later infancy[J].Frontiers in pediatrics, 2017, 5:200.

[82] RUTAYISIRE E, HUANG K, LIU Y, et al.The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants’ life: a systematic review[J].BMC gastroenterology, 2016, 16(1):86.

[83] NAGPAL R, TSUJI H, TAKAHASHI T, et al.Ontogenesis of the gut Microbiota composition in healthy, full-term, vaginally born and breast-fed infants over the first 3 years of life: a quantitative bird’s-eye view[J].Frontiers in microbiology, 2017, 8:1388.

[84] FOUHY F, WATKINS C, HILL C J, et al.Microbiome memory of perinatal factors that affect the gut microbiota four years after birth[J].Nature communications, 2019, 10:1517.

[85] MASARU T, JIRO N.Development of the gut microbiota in infancy and its impact on health in later life[J].Japanese society of allergology, 2017, 66(4):515-522.

[86] TITO R Y, CHAFFRON S, CAENEPEEL C, et al.Population-level analysis of Blastocystis subtype prevalence and variation in the human gut microbiota[J].Gut pathogens, 2019,68(7):1180-1189.

[87] JUNHUA L, HUIJUE J, XIANGHANG C, et al.An integrated catalog of reference genes in the human gut microbiome[J].Nature biotechnology, 2014, 32(8):834-841.

[88] GORVITOVSKAIA A, HOLMES S P, HUSE S M.Interpreting prevotella and bacteroides as biomarkers of diet and lifestyle[J].Microbiome, 2016, 4:15.

[89] FORSTER S C, KUMAR N, ANONYE B O, et al.A human gut bacterial genome and culture collection for improved metagenomic analyses[J].Nature biotechnology, 2019,37(2):186-192.

[90] IIZUMI T, BATTAGLIA T, RUIZ V, et al.Gut microbiome and antibiotics[J].Archives of medical research, 2017, 48:727-734.

[91] VEMURI R, GUNDAMARAJU R, SHASTRI M D, et al.Gut microbial changes,interactions, and their implications on human lifecycle: an ageing perspective[J].BioMed research international, 2018, 20:18.

[92] DINAN T G, CRYAN J F.The microbiome-gut-brain axis in health and disease[J].Gastroenterology clinics of North America, 2017, 46(1):77-89.

[93] SONNENBURG E D, SONNENBURG J L.Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates[J].Cell metabolism,2014, 20(5).

[94] NDEH D, ROGOWSKI A, CARTMELL A, et al.Complex pectin metabolism by gut bacteria reveals novel catalytic functions[J].Nature, 2017, 544(7648):65-70.

[95] LOUIS P, FLINT H J.Formation of propionate and butyrate by the human colonic microbiota[J].Environmental microbiology, 2017, 19(1):29-41.

[96] MILLS S, STANTON C, LANE J A, et al.Precision nutrition and the microbiome, part I:current state of the science[J].Nutrients, 2019, 11(4):923.

[97] STRANDWITZ P, KIM K H, TEREKHOVA D, et al.GABA-modulating bacteria of the human gut microbiota[J].Nature microbiology, 2019, 4(3):396-403.

[98] DE VADDER F, GRASSET E, MANNERÅS-HOLM L, et al.Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks[C]//Proceedings of The National Academy of Sciences of The United States of America, 2018,115:6458-6463.

[99] LAMAS B, RICHARD M L, LEDUCQ V, et al.CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands[J].Nature medicine, 2016, 22(6):598-605.

[100] LAWLEY T D, WALKER A W.Intestinal colonisation resistance[J].Immunology, 2012,138:1-11.

[101] CALEB J K, LEON Z H, ERIC L C, et al.Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J].Cell host &microbe, 2015, 17(5):662-671.

[102] RIVERA-CHÁVEZ F, LILLIAN F Z, FRANZISKA F, et al.Depletion of butyrateproducing clostridia from the gut microbiota drives an aerobic luminal expansion of salmonella[J].Cell host & microbe, 2016, 19(4):445-454.

[103] WALSH C J, GUINANE C M, HILL C, et al.In silico identification of bacteriocin gene clusters in the gastrointestinal tract, based on the Human Microbiome Project’s reference genome database[J].BMC microbial, 2015, 15:183.

[104] BUFFIE C G, BUCCI V, STEIN R R, et al.Precision microbiome reconstitution restores bile acid mediated resistance to clostridium difficile[J].Nature, 2015, 517(7533):205-208.

[105] RIOS D, WOOD M B, LI J, et al.Antigen sampling by intestinal M cells is the principal pathway initiating mucosal IgA production to commensal enteric bacteria[J].Mucosal immunological, 2016, 9:907-916.

[106] DONALDSON G P, LEE S M, MAZMANIAN S K.Gut biogeography of the bacterial microbiota[J].Nature reviews microbiology, 2016, 14:20-32.